PLAINSBORO, N.J., Aug. 15, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® (semaglutide) injection 2.4 mg, ...
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...
Federal regulators are warning about safety concerns amid the rising popularity of drugs like Ozempic and Wegovy for weight loss. The U.S. Food and Drug Administration is warning consumers that ...
The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...
Novo Nordisk's 7.2 mg Wegovy injectable aims to enhance chronic weight management in adults with obesity, using an expedited FDA review process. The Phase III STEP UP trial showed semaglutide 7.2 mg's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback